Journalists

Media & Press relations

Our latest press releases

January 22, 2026

bioMérieux Acquires Accellix to Elevate Pharmaceutical Quality Control and Accelerate Advanced Therapies

bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control. With this strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions that will support the growing advanced therapy market and improve patient outcomes worldwide.

Discover more

Swipe for more

December 04, 2025

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of its immunoassay endocrinology offer for equine health, consisting of VIDAS® Equine INSULIN and VIDAS® Equine ACTH.

Read more
November 05, 2025

Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug-resistant tuberculosis

Oxford Nanopore Technologies and bioMérieux have announced the launch of AmPORE-TB, a Research Use Only (RUO) solution for the rapid characterization of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis complex, using Oxford Nanopore sequencing technology.

Read more
November 04, 2025

Third-Quarter 2025 Business Review

bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2025. Consolidated sales amounted to €2,992 million for the first nine months of 2025 versus €2,871 million for the prior-year period, representing a growth of +4.2% as reported.

Read more